Helixgate

Helixgate

Uncategorized

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. 

Read More

Published

on

Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention. 

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Published

on

Moderna appears to have aligned with the FDA ahead of an advisory committee meeting for its mRNA-based flu vaccine, which the regulator initially turned away in February; biotech IPOs are going gangbusters, including two new records raises in as many weeks; layoffs continue across biopharma; plus much more.

Continue Reading

Uncategorized

PwC declares biopharma ecosystem ‘back to full health’ as M&A buoys sector

Published

on

Precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products, PwC says in a new report. Biotechs should be prepared with a dual-track process with the IPO window now open.

Continue Reading

Uncategorized

Putting the wrong foot forward: 5 tricky interview questions

Published

on

Even something as simple as “Tell me about yourself” can trip up biopharma professionals during job interviews. Two recruiting experts discuss what candidates should and shouldn’t say when answering five specific questions.

Continue Reading
Advertisement

Trending